BRUSSELS Wed Feb 26, 2014 1:14am EST
BRUSSELS Feb 26 (Reuters) - U C B SA : * FY revenue of EUR 3,411 million * FY underlying profitability (recurring EBITDA) up to EUR 689 million * Gross dividend of EUR 1.04 per share (+2%) proposed by board of directors * Revenue 2014 to grow to approx. EUR 3.5-3.6 billion * 2014 recurring EBITDA to increase to approx. EUR 740-770 million. core EPS
expected in the range of EUR 1.90 - 2.05. * Keppra FY net sales of 712 million * Cimzia for inflammatory arthritis indications and crohn's disease increased
FY net sales by 27% to EUR 594 million * FY net sales of the anti-epileptic medicine vimpat increased to EUR 411
BRUSSELS Feb 26 (Reuters) - U C B SA : * FY revenue of EUR 3,411 million * FY underlying profitability (recurring EBITDA) up to EUR 689 million * Gross dividend of EUR 1.04 per share (+2%) proposed by board of directors * Revenue 2014 to grow to approx. EUR 3.5-3.6 billion * 2014 recurring EBITDA to increase to approx. EUR 740-770 million. core EPS
expected in the range of EUR 1.90 - 2.05. * Keppra FY net sales of 712 million * Cimzia for inflammatory arthritis indications and crohn's disease increased
FY net sales by 27% to EUR 594 million * FY net sales of the anti-epileptic medicine vimpat increased to EUR 411
via Smart Health Shop Forum http://ift.tt/N2xsnq
No comments:
Post a Comment